Rapidly progressive glomerulonephritis historical perspective
Rapidly progressive glomerulonephritis Microchapters |
Differentiating Rapidly progressive glomerulonephritis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Rapidly progressive glomerulonephritis historical perspective On the Web |
American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis historical perspective |
FDA on Rapidly progressive glomerulonephritis historical perspective |
CDC on Rapidly progressive glomerulonephritis historical perspective |
Rapidly progressive glomerulonephritis historical perspective in the news |
Blogs on Rapidly progressive glomerulonephritis historical perspective |
Directions to Hospitals Treating Rapidly progressive glomerulonephritis |
Risk calculators and risk factors for Rapidly progressive glomerulonephritis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]
Overview
In 1919 Ernst Goodpasture made case reports about glomerulnophritis and pulmonary haemorrhages. Stanton and Tait from Australia studied these case reports and then named the findings as Goodpasture syndrome in 1958. They gave the anti GBM antibodies classification and discovered RPGN in these cases. In 1960s electron microscopy and immunofluorescence helped to learn RPNG on immunological level.
Historical perspective
- Ernst Goodpasture made case reports about glomerulnophritis and pulmonary haemorrhages in 1919[1].
- Stanton and Tait from Australia studied these case reports and then named the findings as Goodpasture syndrome in 1958.
- They gave the anti GBM antibodies classification and discovered RPGN in these cases.
- In 1960s, electron microscopy and immunofluorescence helped to learn RPNG on immunological level.
References
- ↑ McAdoo SP, Pusey CD (2017). "Anti-Glomerular Basement Membrane Disease". Clin J Am Soc Nephrol. 12 (7): 1162–1172. doi:10.2215/CJN.01380217. PMC 5498345. PMID 28515156.